The ASCEND-HF trial: An acute study of clinical effectiveness of nesiritide and decompensated heart failure

Sanjay Dandamudi, Horng H. Chen

Research output: Contribution to journalReview article

11 Scopus citations


Nesiritide has been approved by the US FDA for the treatment of acute decompensated heart failure since 2001. Subsequently, two meta-analyses questioned its impact on mortality and association with worsening renal function. Therefore, the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial was designed to assess the safety and efficacy of nesiritide in acute decompensated heart failure based on clinically relevant outcomes. In this article, the important findings and lessons learned from this landmark study are reviewed and potential evolving roles for nesiritide and natriuretic peptides in the future of heart failure therapy are proposed.

Original languageEnglish (US)
Pages (from-to)557-563
Number of pages7
JournalExpert Review of Cardiovascular Therapy
Issue number5
StatePublished - May 1 2012



  • heart failure
  • heart failure therapy
  • natriuretic peptides
  • nesiritide

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this